BIOPHARMACEUTICALS

TERIPARATIDE

Teriparatide (API) to accelerate osteoporosis therapy

Background

• Teriparatide (brand name Forteo) is a recombinant DNA form of parathyroid hormone consisting of the 34 amino acids bioactive portion of the hormone, used in the treatment of osteoporosis.
• Lorven technology on Teriparatide would benefit many pharma majors to decrease their cost of peptide production.

Salient features of Lorven’s Teriparatide                                                         

• Application ready Teriparatide biosimilar
• Highly pure (96%), available at an economical price
• Expressed in E. coli expression system
• Yields up to gm/lit.
• Optimized downstream processing

Product Quality

• 100% native confirmation
• Functionally active peptide
• Efficacy matches with the innovator reference drug
• Free from animal-derived components

Safety

E. coli: Genetically highly amenable host organism with BSL-1 maintenance.

Intellectual Property

Patent Application under process. Title: Process for improved expression of biologically active Teriparatide in E. coli expression system by strain engineering.